Monitor future 8-Ks or press releases for TONMYA prescription volume, net revenue, and Medicare coverage updates. The coverage expansion is a necessary but insufficient condition for commercial success — actual script data will determine revenue trajectory.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced a second GPO agreement for TONMYA, effective June 1, 2026, adding ~17 million commercial lives and bringing total commercial coverage to ~52 million lives (29% of U.S. commercial market). TONMYA is also available under Medicaid in most states (~75 million beneficiaries). This expands patient access during the early commercial launch phase but does not provide revenue or prescription data.
Key Facts
- Second GPO agreement effective June 1, 2026, adds ~17 million U.S. commercial lives (10% of ~177 million total commercial lives).
- Total commercial coverage now ~52 million lives (29% of U.S. commercial market).
- TONMYA available under Medicaid in most states, representing ~75 million Medicaid beneficiaries.
- First GPO agreement announced May 6, 2026, provided access to ~35 million commercial lives.
- Discussions with Medicare continue to advance.
Financial Impact
No revenue, prescription, or pricing data disclosed. Coverage expansion is a positive access milestone but unquantified in dollar terms.
Risk Factors
- No revenue or prescription data disclosed — coverage does not guarantee utilization.
- Medicare coverage discussions are ongoing but not finalized.
- Competition from existing fibromyalgia treatments and generic cyclobenzaprine.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027621 |
| Exhibit: ex99-01.htm | 0001493152-26-027621 |
| Document: 0001493152-26-027621-index-headers.html | 0001493152-26-027621 |
| Document: 0001493152-26-027621-index.html | 0001493152-26-027621 |
| Document: 0001493152-26-027621.txt | 0001493152-26-027621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.39 (−5.93%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.39 (−16.04%) |
Oct 2, 2026 25d ago | 8-K | $8.07 | awaiting T+20 | — | $5.39 (+33.21%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.39 (−49.10%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.39 (−59.04%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.19%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.19%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.39 (−49.48%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.39 (−48.02%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.39 (−53.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers